Hamilton Articles
New anticoagulant studies may change current medical practice including use of aspirin and heparin in VTE and to prevent miscarriages
7 December 2009
DOR Bio appoints Brian Hamilton as CMO
23 March 2009
Lunesta misses Ph II efficacy endpoints
16 March 2009
AZ reports good results for Seroquel XR in GAD
8 September 2008
EMEA approves Cymbalta for GAD
1 September 2008
Cymbalta gets nod for GAD in European
7 July 2008
Seroquel XR fares well in MDD and GAD
19 May 2008
AZ submits sNDA for Seroquel to treat GAD
19 May 2008
Canadian charges dropped in contaminated blood case
28 January 2008
Seroquel impresses in MDD and GAD studies
10 December 2007
Public/private partnership key to tackling HIV/AIDS
10 December 2007
New Zealanders' access to new medicines world's worst
3 December 2007
"First survey" of women execs in drug and biotech sectors
19 November 2007
Biomira hires Gary Christianson as COO
23 July 2007
Wyeth's Pristiq extends relapse time in MDD
4 June 2007
US FDA approves Lilly's Cymbalta in GAD
5 March 2007
Encouraging Ph I data for Avalon's AVN944
22 December 2006
Targacept's TRIDMAC improves on Celexa
20 November 2006
Corgenix' AspirinWorks recognised by new patent
28 August 2006
Avalon Pharma appoints J Michael Hamilton as CMO
14 August 2006
Strong Ph III data for Wyeth's desvenlafaxine
5 June 2006
Strong data for Seroquel SSRI/SNRI augmentation
29 May 2006
US FDA commits to PMS; awards contract
17 April 2006
Cymbalta performs well in anxiety study
3 April 2006
Emisphere defeats Lilly in oral PTH dispute
16 January 2006
King Pharma publishes Altace clinical trial results
19 September 2005
ASCOT redefines treatment of cardiovascular risk in hypertension
12 September 2005
Corixa shareholders vote for GSK merger
18 July 2005
Atacand cuts diabetes risk in HF patients
11 July 2005
UK's Xenova accepts takeover offer
4 July 2005
Corixa shareholder says no to GSK offer
27 June 2005
Lilly's Cymbalta: strong performance in elderly
6 June 2005
GSK boosts vaccs ops with $300M Corixa buy
9 May 2005
St John's Wort as effective as paroxetine
28 February 2005
Panel highlights benefits of probiotics
15 November 2004
Collaborative alliance for aspirin resistance testing
15 November 2004
Lexapro as effective as Paxil for GAD
22 March 2004
Sanofi-Synthelabo reveals R&D pipeline with nine compounds in Ph III
23 February 2004
Lexapro cleared for new use by FDA
5 January 2004
Positive new data for Forest's Lexapro
22 December 2003
Forest's Lexapro "has benefit over Effexor"
29 September 2003
Forest's Lexapro "has benefit over Effexor"
29 September 2003
Rob Hamilton promoted at Biogen Canada
19 May 2003
Karo Bio reorganizes R&D posts
3 February 2003
Zyprexa and Prozac effective together
11 May 2001
Management changes at Salix
18 November 1999
OASIS-2 data support Refludan efficacy in UA
15 February 1999
Effexor Shows Rapid Onset Of Efficacy Versus Prozac
6 November 1998
Key To Successful Future Examined At BIO 98
23 June 1998
New Data With B-MS' Serzone
3 July 1997
The Way Ahead For Self-Medication: AESGP Conf
25 June 1997
Amiodarone Cuts Total Mortality Post-MI, CHF
12 June 1997
Creative Bionolecules Appointment
19 March 1997
Clopidogrel Tops Aspirin For Atherosclerotic Disease
18 November 1996
Organon's Remeron Is "Better Than Prozac"
30 September 1996
Mirtazepine Nears US Approval; 1st Alpha2 Blocker Antidepressant
30 October 1995
OASIS Pilot Results Suggest Hirudin Benefit
11 September 1995
Generics: A Passage Through Time
4 September 1995
USA "No Longer Leads The World In OTCs"
8 May 1995
Oncogene Blockers Near Clinical Trials
27 March 1995
SB's Seroxat Better Tolerated Than Faverin?
5 December 1994
Effexor Superior To Prozac?
10 October 1994
FORTHCOMING MEETINGS
9 May 1994
GPIA APPOINTMENT AND MEMBERS
11 April 1994
GENERIC COMPETITION HITS SYNTEX
7 March 1994
ANTIBIOTIC RESISTANCE RESEARCH
14 February 1994
VITAMIN E AND RAMIPRIL TRIAL
7 February 1994
SYNTEX CHIEF SPEAKS ON PRODUCT PROSPECTS
24 January 1994
FIRST OTC NAPROXEN CLEARED FOR SALE
17 January 1994
HAMILTON RECEIVES ANDA APPROVAL
13 September 1993
BOEH MANNHEIM REORGANIZES
12 October 1992
Cancer may be caused by single enzyme
15 June 1992
BAYER DIAGNOSTICS' NEW INSTRUMENT
6 April 1992
BAYER DIAGNOSTICS' NEW INSTRUMENT
6 April 1992
FORTHCOMING MEETINGS IN THE UK
20 January 1992
Showing 1-90 of 90 articles
- 1
- Encouraging results with Sangamo's SB-728-T in HIV treatment
- Boehringer Ingelheim transitions to propellant-free Combivent Respimat; names new BMD member
- Bristol-Myers' data on Yervoy and nivolumab causes a stir
- Sanofi prepares for regulatory filing of MF candidate on positive JAKARTA study results
- Neovacs moving forward in rheumatoid arthritis, say analysts
